Aura Biosciences (NASDAQ:AURA) Shares Gap Down - What's Next?

Aura Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aura Biosciences shares opened lower at $6.51, down from the prior close of $6.98, but later traded at $6.945.
  • Analysts have a “Moderate Buy” consensus and an average price target of $17.50; ratings include three Buys and one Sell.
  • The company reported a quarterly loss of $0.29 per share, beating the $0.37 loss analysts expected. Institutional investors own 96.75% of its shares.
  • Five stocks we like better than Aura Biosciences.

Shares of Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $6.98, but opened at $6.51. Aura Biosciences shares last traded at $6.9450, with a volume of 49,293 shares.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AURA. Citigroup reissued a "market outperform" rating on shares of Aura Biosciences in a research report on Tuesday, November 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Aura Biosciences in a research report on Monday, October 12th. Wall Street Zen raised Aura Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, November 14th. Finally, HC Wainwright reduced their price objective on shares of Aura Biosciences from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.50.

Check Out Our Latest Stock Report on Aura Biosciences

Aura Biosciences Price Performance

The stock's 50 day simple moving average is $6.53 and its 200-day simple moving average is $6.80. The company has a market capitalization of $711.32 million, a PE ratio of -4.17 and a beta of 0.41.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.08. On average, equities analysts predict that Aura Biosciences, Inc. will post -1.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Montanova Capital LLC boosted its position in Aura Biosciences by 64.8% during the 2nd quarter. Montanova Capital LLC now owns 7,206,217 shares of the company's stock worth $51,164,000 after acquiring an additional 2,833,333 shares during the period. Frazier Life Sciences Management L.P. lifted its stake in Aura Biosciences by 39.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 7,100,000 shares of the company's stock valued at $50,410,000 after buying an additional 2,000,000 shares during the period. BlackRock Inc. bought a new stake in shares of Aura Biosciences during the 2nd quarter worth approximately $33,424,000. Nantahala Capital Management LLC raised its position in shares of Aura Biosciences by 29.0% during the third quarter. Nantahala Capital Management LLC now owns 3,807,300 shares of the company's stock worth $23,910,000 after acquiring an additional 856,270 shares during the last quarter. Finally, Jupiter Topco LLC bought a new position in shares of Aura Biosciences in the second quarter valued at approximately $17,788,000. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Company Profile

(Get Free Report)

Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Aura Biosciences Right Now?

Before you consider Aura Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.

While Aura Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines